Literature DB >> 19257830

Genetic hypercalciuric stone-forming rats have a primary decrease in BMD and strength.

Marc Grynpas1, Stephen Waldman, Douglas Holmyard, David A Bushinsky.   

Abstract

Kidney stone patients often have a decrease in BMD. It is unclear if reduced BMD is caused by a primary disorder of bone or dietary factors. To study the independent effects of hypercalciuria on bone, we used genetic hypercalciuric stone-forming (GHS) rats. GHS and control (Ctl) rats were fed a low Ca (0.02% Ca, LCD) or a high Ca (1.2% Ca, HCD) diet for 6 wk in metabolic cages. All comparisons are to Ctl rats. Urine Ca was greater in the GHS rats on both diets. GHS fed HCD had reduced cortical (humerus) and trabecular (L(1)-L(5) vertebrae) BMD, whereas GHS rats fed LCD had a reduction in BMD similar to Ctl. GHS rats fed HCD had a decrease in trabecular volume and thickness, whereas LCD led to a approximately 20-fold increase in both osteoid surface and volume. GHS rats fed HCD had no change in vertebral strength (failure stress), ductibility (failure strain), stiffness (modulus), or toughness, whereas in the humerus, there was reduced ductibility and toughness and an increase in modulus, indicating that the defect in mechanical properties is mainly manifested in cortical, rather than trabecular, bone. GHS rat cortical bone is more mineralized than trabecular bone and LCD led to a decrease in the mineralization profile. Thus, the GHS rats, fed an ample Ca diet, have reduced BMD with reduced trabecular volume, mineralized volume, and thickness, and their bones are more brittle and fracture prone, indicating that GHS rats have an intrinsic disorder of bone that is not secondary to diet.

Entities:  

Mesh:

Year:  2009        PMID: 19257830      PMCID: PMC2718798          DOI: 10.1359/jbmr.090223

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  52 in total

1.  Calcium clearance as a function of sodium clearance in the dog.

Authors:  M WALSER
Journal:  Am J Physiol       Date:  1961-05

2.  Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats.

Authors:  D A Bushinsky; K J Neumann; J Asplin; N S Krieger
Journal:  Kidney Int       Date:  1999-01       Impact factor: 10.612

Review 3.  Kidney stone disease.

Authors:  Fredric L Coe; Andrew Evan; Elaine Worcester
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

Review 4.  Genetic hypercalciuric stone-forming rats.

Authors:  D A Bushinsky
Journal:  Curr Opin Nephrol Hypertens       Date:  1999-07       Impact factor: 2.894

5.  Urinary calcium is a determinant of bone mineral density in elderly men participating in the InCHIANTI study.

Authors:  Giuseppe Vezzoli; Laura Soldati; Teresa Arcidiacono; Annalisa Terranegra; Rita Biasion; Cosimo Roberto Russo; Fulvio Lauretani; Stefania Bandinelli; Benedetta Bartali; Antonio Cherubini; Daniele Cusi; Luigi Ferrucci
Journal:  Kidney Int       Date:  2005-05       Impact factor: 10.612

6.  Regulation of renal calcium receptor gene expression by 1,25-dihydroxyvitamin D3 in genetic hypercalciuric stone-forming rats.

Authors:  Jim J Yao; Shaochun Bai; Alexander J Karnauskas; David A Bushinsky; Murray J Favus
Journal:  J Am Soc Nephrol       Date:  2005-03-23       Impact factor: 10.121

7.  Mechanism and function of high vitamin D receptor levels in genetic hypercalciuric stone-forming rats.

Authors:  Alexander J Karnauskas; Johannes P T M van Leeuwen; Gert-Jan C M van den Bemd; Paru P Kathpalia; Hector F DeLuca; David A Bushinsky; Murray J Favus
Journal:  J Bone Miner Res       Date:  2004-11-29       Impact factor: 6.741

8.  Increased dietary oxalate does not increase urinary calcium oxalate saturation in hypercalciuric rats.

Authors:  D A Bushinsky; M A Bashir; D R Riordon; Y Nakagawa; F L Coe; M D Grynpas
Journal:  Kidney Int       Date:  1999-02       Impact factor: 10.612

9.  Effect of etidronate treatment on bone mass of male nephrolithiasis patients with idiopathic hypercalciuria and osteopenia.

Authors:  I P Heilberg; L A Martini; S H Teixeira; V L Szejnfeld; A B Carvalho; R Lobão; S A Draibe
Journal:  Nephron       Date:  1998-08       Impact factor: 2.847

10.  Increased urinary saturation and kidney calcium content in genetic hypercalciuric rats.

Authors:  D A Bushinsky; M Kim; N E Sessler; Y Nakagawa; F L Coe
Journal:  Kidney Int       Date:  1994-01       Impact factor: 10.612

View more
  15 in total

1.  Expression of fibroblast growth factor 23, vitamin D receptor, and sclerostin in bone tissue from hypercalciuric stone formers.

Authors:  Viviane Barcellos Menon; Rosa Maria Affonso Moysés; Samirah Abreu Gomes; Aluizio Barbosa de Carvalho; Vanda Jorgetti; Ita Pfeferman Heilberg
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-24       Impact factor: 8.237

2.  Bisphosphonates in the management of idiopathic hypercalciuria associated with osteoporosis: a new trick from an old drug.

Authors:  Gerolamo Bianchi; Andrea Giusti; Giulio Pioli; Antonella Barone; Ernesto Palummeri; Giuseppe Girasole
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-02       Impact factor: 5.346

3.  Chlorthalidone Is Superior to Potassium Citrate in Reducing Calcium Phosphate Stones and Increasing Bone Quality in Hypercalciuric Stone-Forming Rats.

Authors:  Nancy S Krieger; John R Asplin; Ignacio Granja; Felix M Ramos; Courtney Flotteron; Luojing Chen; Tong Tong Wu; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2019-05-17       Impact factor: 10.121

Review 4.  Idiopathic hypercalciuria and bone health.

Authors:  Laura E Ryan; Steven W Ing
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

5.  Effect of Potassium Citrate on Calcium Phosphate Stones in a Model of Hypercalciuria.

Authors:  Nancy S Krieger; John R Asplin; Kevin K Frick; Ignacio Granja; Christopher D Culbertson; Adeline Ng; Marc D Grynpas; David A Bushinsky
Journal:  J Am Soc Nephrol       Date:  2015-04-08       Impact factor: 10.121

6.  Chlorthalidone improves vertebral bone quality in genetic hypercalciuric stone-forming rats.

Authors:  David A Bushinsky; Thomas Willett; John R Asplin; Christopher Culbertson; Sara P Y Che; Marc Grynpas
Journal:  J Bone Miner Res       Date:  2011-08       Impact factor: 6.741

7.  1,25(OH)₂D₃ induces a mineralization defect and loss of bone mineral density in genetic hypercalciuric stone-forming rats.

Authors:  Adeline H Ng; Kevin K Frick; Nancy S Krieger; John R Asplin; Madison Cohen-McFarlane; Christopher D Culbertson; Kelly Kyker-Snowman; Marc D Grynpas; David A Bushinsky
Journal:  Calcif Tissue Int       Date:  2014-01-31       Impact factor: 4.333

8.  The relation between bone and stone formation.

Authors:  Nancy S Krieger; David A Bushinsky
Journal:  Calcif Tissue Int       Date:  2012-12-18       Impact factor: 4.333

9.  Persistence of 1,25D-induced hypercalciuria in alendronate-treated genetic hypercalciuric stone-forming rats fed a low-calcium diet.

Authors:  Kevin K Frick; John R Asplin; Christopher D Culbertson; Ignacio Granja; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-26

10.  Increased biological response to 1,25(OH)(2)D(3) in genetic hypercalciuric stone-forming rats.

Authors:  Kevin K Frick; John R Asplin; Murray J Favus; Christopher Culbertson; Nancy S Krieger; David A Bushinsky
Journal:  Am J Physiol Renal Physiol       Date:  2013-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.